Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Corban, et al v. Sarepta Therapeutics, Inc., et al
Case Number:
16-1658
Court:
Nature of Suit:
3850 Securities/Commodities/Exchange
Companies
Sectors & Industries:
-
October 12, 2017
1st Circ. Won't Rethink Ending Sarepta Securities Suit
The First Circuit refused Wednesday to reconsider its August decision upholding the dismissal of a putative securities class action accusing drugmaker Sarepta Therapeutics Inc. of misleading investors over the possibility of government approval for its muscular dystrophy drug eteplirsen.
-
August 22, 2017
1st Circ. Affirms Dismissal Of Sarepta Securities Suit
The First Circuit on Tuesday upheld the dismissal of a putative securities class action against drugmaker Sarepta Therapeutics Inc., saying that despite five tries, the plaintiffs failed to plead a "cogent inference of scienter" that the company misled investors over the possibility of government approval for its muscular dystrophy drug eteplirsen.